Monday, June 15, 2026

Discover the Breakthroughs of Korea’s ARPA-H Project at BIO KOREA 2026!

The K-Health Future Promotion Team will unveil interim results of the Korean-style ARPA-H project at BIO KOREA 2026, addressing healthcare challenges.

North Korea Tests Upgraded Tactical Missile Hwasong-11R: What It Means for Military Strategy

North Korea tested the Hwasong-11R missile to enhance warhead effectiveness, with Kim Jong Un emphasizing military capabilities.

U.S. Defense Official Colin Kahl to Discuss Security Strategies in South Korea and Japan: What’s on the Agenda?

Elbridge Colby will visit South Korea and Japan to discuss U.S.-South Korea alliance and national security strategy under Trump.

Tag: solid tumors

Curocell’s RIMQARTO®: The First CAR-T Therapy in Korea, with Plans for Global Release

Curocell aims to lead in CAR-T therapies with RIMQARTO's approval, focusing on solid tumors and global expansion strategies.

SillaJen’s Breakthrough Cancer BAL0891 Drug Set for ASCO 2026 Reveal

SillaJen's anticancer drug BAL0891 will be presented at the ASCO Annual Meeting, currently in Phase 1 trials for solid tumors and AML.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

New Drug Candidate Shows Promise Against Solid Tumors by Eliminating M2 Macrophages

Researchers have developed a peptide drug that targets M2 macrophages, enhancing solid tumor immunotherapy effectiveness.

Top News

- Our Sponsors Ad -

Follow us